Notably, SBI patients who reported cognitive impairment had significantly lower median titers of anti-α1AR (12 vs. 15, p = 0.036), anti-β1AR (9 vs. 23, p < 0.001), and anti-M4R (5 vs. 9, p = 0.001) in comparison to healthy controls without SBIs. This evidence concerns the gene CHRM4 and Cognitive impairment.